Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The primary objective of early drug discovery is to associate druggable target space with a desired phenotype. The inability to efficiently associate these often leads to failure early in the drug discovery process. In this proof-of-concept study, the most tractable starting points for drug discovery within the NF-κB pathway model system were identified by integrating affinity selection-mass spectrometry (AS-MS) with functional cellular assays. The AS-MS platform Automated Ligand Identification System (ALIS) was used to rapidly screen 15 NF-κB proteins in parallel against large-compound libraries. ALIS identified 382 target-selective compounds binding to 14 of the 15 proteins. Without any chemical optimization, 22 of the 382 target-selective compounds exhibited a cellular phenotype consistent with the respective target associated in ALIS. Further studies on structurally related compounds distinguished two chemical series that exhibited a preliminary structure-activity relationship and confirmed target-driven cellular activity to NF-κB1/p105 and TRAF5, respectively. These two series represent new drug discovery opportunities for chemical optimization. The results described herein demonstrate the power of combining ALIS with cell functional assays in a high-throughput, target-based approach to determine the most tractable drug discovery opportunities within a pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crosstalk in NF-κB Signaling Pathways
Oeckinghaus, A., Hayden, M. S., & Ghosh, S. (2011) · Nature Immunology · doi:10.1038/ni.2065 · Cited by 1,942
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514 · cited 1×
“Given the unsustainability of this business model, recent retrospective analyses have focused on identification of the best processes by which to discover novel therapeutics.(1,3) Multiple culprits throughout the drug discovery process contribute to this inefficiency.”
BackgroundThe application of Tet repressor in prokaryotic gene regulation and expression
Bertram, R., & Hillen, W. (2008) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2007.00001.x · Cited by 160
Cited by
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Exploring new targets and chemical space with affinity selection-mass spectrometry
Prudent, R., Annis, D. A., Dandliker, P. J., Ortholand, J.-Y., & Roche, D. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-00229-2 · Cited by 104
Self-citationLu, Y., Qin, S., Zhang, B., Dai, A., Cai, X., Ma, M., Gao, Z.-G., Yang, D., Stevens, R. C., Jacobson, K. A., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00477 · Cited by 39
Gabriel, J., Höfner, G., & Wanner, K. T. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00665 · Cited by 20
“…MS. ALIS has been successfully employed primarily for soluble proteins, but in some cases also for membrane-bound protein targets and allows—with its outstanding high throughput capacity—to screen thousands of compounds per hour (Whitehurst et al., 2006; Kutilek et al., 2016; Walker et al., 2017).”
BackgroundGabriel, J., Höfner, G., & Wanner, K. T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112598 · Cited by 3
Metadata
- Authors
- Kutilek, V. D., Andrews, C. L., Richards, M. P., Xu, Z., Sun, T., Chen, Y., Hashke, A., Smotrov, N., Fernandez, R., Nickbarg, E. B., Chamberlin, C., Sauvagnat, B., Curran, P. J., Boinay, R., Saradjian, P., Allen, S. J., Byrne, N., Elsen, N. L., Ford, R. E., Hall, D. L., Kornienko, M., Rickert, K. W., Sharma, S., Shipman, J. M., Lumb, K. J., Coleman, K., Dandliker, P. J., Kariv, I., & Beutel, B.
- Venue
- SLAS Discovery
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 21
- Issue
- 6
- Pages
- 608-619
- ISSN
- 2472-5552 (ISSN-L)
- OpenAlex
- W2295441452
- Cited by
- 32
- References
- 4
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway. https://app.cochat.ai/papers/10.1177/1087057116637353
- The paper
- Kutilek, V. D., Andrews, C. L., Richards, M. P., Xu, Z., Sun, T., Chen, Y., Hashke, A., Smotrov, N., Fernandez, R., Nickbarg, E. B., Chamberlin, C., Sauvagnat, B., Curran, P. J., Boinay, R., Saradjian, P., Allen, S. J., Byrne, N., Elsen, N. L., Ford, R. E., . . . Beutel, B. (2016). Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway. SLAS Discovery. https://doi.org/10.1177/1087057116637353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.